🔎 Trials Near Me

Home › Urothelial (Transitional Cell) Carcinoma › California › San Diego

Urothelial (Transitional Cell) Carcinoma clinical trials in San Diego, CA

5 studies for Urothelial (Transitional Cell) Carcinoma are looking for participants at sites in and around San Diego (within about 30 miles). Open a study to see who can join and how to contact the study team.

Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →

Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

RecruitingPhase 1/2
  • UC San Diego Medical Center - Bankers Hill, San Diego
  • UC San Diego McGrath Outpatient Pavilion - Hillcrest, San Diego
  • UC San Diego Medical Center- Hillcrest, San Diego
  • and 7 more
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07421700

Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy

RecruitingPhase 1
  • UC San Diego Moores Cancer Center, La Jolla · 11 mi away
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT06439836

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

RecruitingPhase 1
  • Scripps Health, San Diego
Ages 18 and older · All sexes · Updated Sep 10, 2026 · NCT06293898

A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

RecruitingPhase 2
  • Kaiser Permanente San Diego Mission Road (Regulatory and Lab Supplies), San Diego
  • Kaiser Permanente Zion Medical Center, San Diego
Ages 18 and older · All sexes · Updated Jul 22, 2026 · NCT04879329

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

RecruitingObservational study
  • Massive Bio SYNERGY-AI site, La Jolla · 11 mi away
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774

Urothelial (Transitional Cell) Carcinoma trials in other cities

Other studies in San Diego

From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.